Naoharu Mori1, Keisuke Maeda2,3, Yasuyuki Fukami4, Remi Matsuyama5, Tomoyuki Nonogaki2,6, Ryoko Kato2,6, Yuria Ishida2,7, Akio Shimizu2,8, Junko Ueshima2,9, Ayano Nagano2,10. 1. Department of Palliative and Supportive Medicine, Graduate School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan. nmori@aichi-med-u.ac.jp. 2. Department of Palliative and Supportive Medicine, Graduate School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan. 3. Department of Geriatric Medicine, Hospital, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan. 4. Department of Gastroenterological Surgery, Department of Surgery, Aichi Medical University, Nagakute, Aichi, Japan. 5. Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan. 6. Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan. 7. Department of Nutrition, Aichi Medical University Hospital, Nagakute, Aichi, Japan. 8. Department of Nutrition, Hamamatsu City Rehabilitation Hospital, Hamamatsu, Shizuoka, Japan. 9. Department of Clinical Nutrition and Food Services, NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan. 10. Department of Nursing, Nishinomiya Kyoritsu Neurosurgical Hospital, Nishinomiya, Japan.
Abstract
PURPOSE: A high score determined by SARC-F, a simple screening questionnaire for sarcopenia, has been reportedly associated with worse medical outcomes. However, information regarding whether high SARC-F scores are associated with a poor prognosis in patients with advanced cancer remains limited. We clarified whether a SARC-F score ≥ 4 predicts poor prognosis in patients with cancer receiving palliative care. METHODS: We conducted a retrospective cohort study of patients with cancer who received palliative care at a university hospital between May 2019 and April 2020. Patient characteristics including age, sex, height, weight, cancer type, serum albumin level, C-reactive protein level, presence of edema, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS), SARC-F score, history of anticancer therapy, and clinical outcomes were collected from electronic medical records. RESULTS: Of 304 patients, 188 had a SARC-F score < 4, and 116 patients had a SARC-F score ≥ 4. The overall survival of patients with a SARC-F score ≥ 4 was 40 days (95% CI 29-47), which was significantly worse than 121 days (95% CI 95-156) for patients with a SARC-F score < 4 (p < 0.001). SARC-F score ≥ 4 (hazard ratio: HR 1.56), edema (HR 1.94), head and neck cancer (HR 0.51), C-reactive protein (HR 1.05), ECOG-PS ≥ 3 (HR 1.47), and radiotherapy (HR 0.52) were associated with overall survival. The ability to climb stairs was a SARC-F sub-item significantly associated with mortality (HR 1.59). CONCLUSION: The SARC-F questionnaire is a useful predictor of prognosis for patients with cancer receiving palliative care because a SARC-F ≥ 4 score predicts worse overall survival.
PURPOSE: A high score determined by SARC-F, a simple screening questionnaire for sarcopenia, has been reportedly associated with worse medical outcomes. However, information regarding whether high SARC-F scores are associated with a poor prognosis in patients with advanced cancer remains limited. We clarified whether a SARC-F score ≥ 4 predicts poor prognosis in patients with cancer receiving palliative care. METHODS: We conducted a retrospective cohort study of patients with cancer who received palliative care at a university hospital between May 2019 and April 2020. Patient characteristics including age, sex, height, weight, cancer type, serum albumin level, C-reactive protein level, presence of edema, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS), SARC-F score, history of anticancer therapy, and clinical outcomes were collected from electronic medical records. RESULTS: Of 304 patients, 188 had a SARC-F score < 4, and 116 patients had a SARC-F score ≥ 4. The overall survival of patients with a SARC-F score ≥ 4 was 40 days (95% CI 29-47), which was significantly worse than 121 days (95% CI 95-156) for patients with a SARC-F score < 4 (p < 0.001). SARC-F score ≥ 4 (hazard ratio: HR 1.56), edema (HR 1.94), head and neck cancer (HR 0.51), C-reactive protein (HR 1.05), ECOG-PS ≥ 3 (HR 1.47), and radiotherapy (HR 0.52) were associated with overall survival. The ability to climb stairs was a SARC-F sub-item significantly associated with mortality (HR 1.59). CONCLUSION: The SARC-F questionnaire is a useful predictor of prognosis for patients with cancer receiving palliative care because a SARC-F ≥ 4 score predicts worse overall survival.
Authors: Y Ishida; K Maeda; T Nonogaki; A Shimizu; Y Yamanaka; R Matsuyama; R Kato; J Ueshima; K Murotani; N Mori Journal: J Nutr Health Aging Date: 2020 Impact factor: 4.075
Authors: Ioannis Mintziras; Michael Miligkos; Sabine Wächter; Jerena Manoharan; Elisabeth Maurer; Detlef Klaus Bartsch Journal: Int J Surg Date: 2018-09-25 Impact factor: 6.071
Authors: Ryan D Nipp; Georg Fuchs; Areej El-Jawahri; Julia Mario; Fabian M Troschel; Joseph A Greer; Emily R Gallagher; Vicki A Jackson; Avinash Kambadakone; Theodore S Hong; Jennifer S Temel; Florian J Fintelmann Journal: Oncologist Date: 2017-09-21
Authors: Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni Journal: Age Ageing Date: 2019-01-01 Impact factor: 10.668
Authors: Ana Paula Trussardi Fayh; Francisco Felipe de Oliveira Guedes; Guilherme Carlos Filgueira Calado; Sandra Azevedo Queiroz; Marina Gabriely Gomes Barbosa Anselmo; Iasmin Matias de Sousa Journal: Nutrients Date: 2022-07-30 Impact factor: 6.706